Abstract
Abstract
Objectives
The aim of this study was to deliver insights from multiple stakeholders into actual and future collaboration for health technology assessment (HTA) in general and in oncology in particular.
Methods
Eighteen semi-structured interviews were conducted with experts from European HTA bodies (HTAbs), former board members of the European Network for Health Technology Assessment (EUnetHTA), and representatives from the pharmaceutical industry, a regulatory agency, academia, and patient organizations. The stakeholders were asked about their support of the EUnetHTA’s intent, about the general strengths and challenges of the EUnetHTA and its Joint Action 3 (JA 3), the strengths and challenges of the clinically oriented HTA collaboration in oncology during JA 3 across the technology life cycle, about future challenges to HTA in oncology with consequences for collaboration, and about collaboration in the economic domains of HTA. The transcribed interviews were analyzed qualitatively.
Results
The participants perceived the intention and work quality of the EUnetHTA as positive. The experts described methodological, procedural, and capacity challenges in early dialogues (EDs) and rapid relative effectiveness assessments (REAs) meant to analyze clinical effectiveness in oncology. The majority attached increasing importance to collaboration in the future to cope with the uncertainty of HTA. Several stakeholders also proposed the incorporation of joint postlaunch evidence generation (PLEG) activities. Some gave sporadic suggestions for voluntary nonclinical collaboration as well.
Conclusion
Stakeholders’ continued readiness to discuss the remaining challenges to and sufficient resources for implementing HTA regulation, as well as further cooperative expansion along the technology life cycle, are necessary for improved HTA collaboration in Europe.
Publisher
Cambridge University Press (CUP)
Reference20 articles.
1. Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries
2. 19. European Network for Health Technology Assessment (EUnetHTA) [Internet] Engaging stakeholders in EUnetHTA. A summary of external stakeholder engagement activities in EUnetHTA Joint Action 3. 2021 [cited 2022 May]. Available from: https://www.eunethta.eu/wp-content/uploads/2021/05/Engaging-stakeholders-in-EUnetHTA-Joint-Action-3.pdf.
3. The new definition of health technology assessment: A milestone in international collaboration
4. 4. European Network for Health Technology Assessment (EUnetHTA) . A future model of HTA cooperation. Final white paper [Internet]. Diemen, the Netherlands: EUnetHTA, 2021; 125 [cited 2022 Jun]. Available from: https://www.eunethta.eu/wp-content/uploads/2021/09/FMC-HTA-WHITE-PAPER-FOR-PUBLICATION.pdf.